These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6413408)

  • 1. Antibacterial activity of microbicidal cationic proteins 1 and 2, natural peptide antibiotics of rabbit lung macrophages.
    Lehrer RI; Selsted ME; Szklarek D; Fleischmann J
    Infect Immun; 1983 Oct; 42(1):10-4. PubMed ID: 6413408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens.
    Fluit AC; Schmitz FJ; Verhoef J;
    Int J Antimicrob Agents; 2001 Aug; 18(2):147-60. PubMed ID: 11516938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
    Hiraoka M; Masuyoshi S; Tomatsu K; Inoue M; Mitsuhashi S
    Eur J Clin Microbiol; 1987 Oct; 6(5):559-63. PubMed ID: 3501756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of Achillea clavennae essential oil against respiratory tract pathogens.
    Skocibusić M; Bezić N; Dunkić V; Radonić A
    Fitoterapia; 2004 Dec; 75(7-8):733-6. PubMed ID: 15567252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
    Benson CA; Segreti J; Beaudette FE; Hines DW; Goodman LJ; Kaplan RL; Trenholme GM
    Antimicrob Agents Chemother; 1987 Feb; 31(2):328-30. PubMed ID: 2952063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.
    Ritchie DJ; Hopefl AW; Milligan TW; Byrne JE; Maddux MS
    Clin Ther; 1993; 15(1):107-13. PubMed ID: 8458040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of cefcanel.
    Bergan T; da Fonseca J
    Chemotherapy; 1993; 39(2):96-104. PubMed ID: 8458252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG
    Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabbit CAP18 derived peptides inhibit gram negative and gram positive bacteria.
    Larrick JW; Hirata M; Shimomoura Y; Yoshida M; Zheng H; Zhong J; Wright SC
    Prog Clin Biol Res; 1994; 388():125-35. PubMed ID: 7831354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ; Jin YF
    J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin.
    Van der Auwera P; Klastersky J
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1061-8. PubMed ID: 3116918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-defensin derived cationic antimicrobial peptides with potent killing activity against gram negative and gram positive bacteria.
    Yang M; Zhang C; Zhang MZ; Zhang S
    BMC Microbiol; 2018 Jun; 18(1):54. PubMed ID: 29871599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.
    Inoue E; Mitsuhashi S
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1974-9. PubMed ID: 7811005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial activities of piperacillin in several fresh clinical isolates].
    Matsuzaki K; Koyama H; Omika K; Hasegawa M; Sato Y; Kobayashi I; Kaku M
    Jpn J Antibiot; 2000 Aug; 53(8):573-81. PubMed ID: 11070819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.